Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HBB | P68871 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL713090 | 1.00 | KDM4E (0.53) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| SCHEMBL712563 | 0.92 | KDM4E (0.58) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| SCHEMBL712564 | 0.92 | KDM4E (0.58) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| SCHEMBL710899 | 0.86 | KDM4E (0.52) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| SCHEMBL710900 | 0.86 | KDM4E (0.52) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| SCHEMBL711597 | 0.86 | KDM4E (0.58) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| SCHEMBL711598 | 0.86 | KDM4E (0.58) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| SCHEMBL712538 | 0.84 | KDM4E (0.52) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| SCHEMBL712539 | 0.84 | KDM4E (0.52) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| SCHEMBL711675 | 0.84 | KDM4E (0.49) | KDM4EALDH1A1HPGDADRA1AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6576763-B1 | Stereospecific acylation; viricides for herpes and retroviruses | MEDIVIR AB (SE) | 2003-06-10 | — | — | US | claimed |
| US-20120123119-A1 | ACYCLIC NUCLEOSIDE DERIVATIVES | MEDIVIR AB (SE) | 2012-05-17 | — | — | US | disclosed |
| US-8124609-B2 | Acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2012-02-28 | — | — | US | disclosed |
| US-20090076041-A1 | ACYCLIC NUCLEOSIDE DERIVATIVES | MEDIVIR AB (SE) | 2009-03-19 | — | — | US | disclosed |
| US-7432274-B2 | Acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2008-10-07 | — | — | US | disclosed |
| US-7189849-B2 | Synthesis of acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2007-03-13 | — | — | US | disclosed |
| US-20050250795-A1 | Synthesis of acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2005-11-10 | — | — | US | disclosed |
| US-6878844-B2 | Synthesis of acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2005-04-12 | — | — | US | disclosed |
| US-20040248910-A1 | Synthesis of acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2004-12-09 | — | — | US | disclosed |
| US-20040132749-A1 | Acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2004-07-08 | — | — | US | disclosed |
| EP-0880521-B1 | SYNTHESIS OF ACYCLIC NUCLEOSIDES | MEDIVIR AB (SE) | 2003-01-22 | — | — | EP | disclosed |
| US-20020188125-A1 | Acyclic nucleoside derivatives | MEDIVIR AB | 2002-12-12 | — | — | US | disclosed |
| US-6255312-B1 | VIRICIDES | MEDIVIR AB (SE) | 2001-07-03 | — | — | US | disclosed |
| US-6184376-B1 | POTENT ANTIVIRALS, ESPECIALLY AGAINST HERPES INFECTIONS, SUCH AS THOSE CAUSED BY VARICELLA ZOSTER VIRUS, HERPES SIMPLEX, EPSTEIN-BARR VIRUS, HERPES TYPE 6 (HHV-6) AND TYPE 8 (HHV-8). SHINGLES IN THE ELDERLY OR CHICKEN POX IN THE YOUNG | MEDIVER AB (SE) | 2001-02-06 | — | — | US | disclosed |
| EP-0971923-A2 | SYNTHESIS OF ACYCLIC NUCLEOSIDE DERIVATIVES | MEDIVIR AB (SE) | 2000-01-19 | — | — | EP | disclosed |
| EP-0888348-A1 | ACYCLIC NUCLEOSIDE DERIVATIVES | Medivir Aktiebolag (SE) | 1999-01-07 | — | — | EP | disclosed |
| EP-0880521-A1 | SYNTHESIS OF ACYCLIC NUCLEOSIDES | Medivir Aktiebolag (SE) | 1998-12-02 | — | — | EP | disclosed |
| WO-1998034917-A2 | SYNTHESIS OF ACYCLIC NUCLEOSIDE DERIVATIVES | MEDIVIR AB (SE) | 1998-08-13 | — | — | WO | disclosed |
| WO-1997030052-A1 | SYNTHESIS OF ACYCLIC NUCLEOSIDES | MEDIVIR AB (SE) | 1997-08-21 | — | — | WO | disclosed |
| WO-1997030051-A1 | ACYCLIC NUCLEOSIDE DERIVATIVES | MEDIVIR AB (SE) | 1997-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076041-A1 | ACYCLIC NUCLEOSIDE DERIVATIVES | NUDT1, PNP, NSUN2 | KDM4E 4336/4885ALDH1A1 2140/4885HPGD 1026/4885 |
| US-20120123119-A1 | ACYCLIC NUCLEOSIDE DERIVATIVES | NUDT1, PNP, NSUN2 | KDM4E 4317/4885ALDH1A1 2200/4885HPGD 1066/4885 |
| US-20040132749-A1 | Acyclic nucleoside derivatives | NSUN2, NUDT1, PNP | KDM4E 4353/4885ALDH1A1 2049/4885HPGD 1603/4885 |
| US-20040248910-A1 | Synthesis of acyclic nucleoside derivatives | NSUN2, SLC28A1, NUDT1 | KDM4E 4410/4885ALDH1A1 2176/4885HPGD 1298/4885 |
| US-20050250795-A1 | Synthesis of acyclic nucleoside derivatives | ASNS, NUDT1, PNP | KDM4E 4268/4885ALDH1A1 2194/4885HPGD 943/4885 |
| US-20020188125-A1 | Acyclic nucleoside derivatives | NSUN2, NUDT1, PNP | KDM4E 4279/4885ALDH1A1 2233/4885HPGD 1619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.